The healthcare group Vamed, whose planned sale of the rehabilitation business to the French private equity company PAI has led to political discontent in this country, announced extensive changes on Thursday: Klaus Schuster and Frank-Michael Frede are resigning from their board positions in order to take on management roles at the future companies. The CEO position of Vamed AG has been taken over by board member Moritz Timothy Gärtner.
More on the subject:
Milan Manduch is a new member of the Vamed board. The three-person Vamed board team has been made up of Gärtner, Andreas Wortmann (finance) and Manduch (operational business) since August 1st.
Last week, the “Standard” reported that as part of the split of Vamed, the management apparently also wants to uncover abuses within the group. To make this easier, around 300 employees at the Vienna headquarters were promised by letter that there would be no employment or civil law consequences if they were involved in abuses and provided information about them. The “conclusion of an amnesty agreement” was offered by mid-October. At the time, it was said: “This is a standard procedure in connection with the reversal of project business and associated contractual constellations.”
Vamed is filleted
The Vamed Group, with around 20,000 employees, was filleted by Fresenius in May this year and divided up into different companies. The two construction companies Porr and Strabag acquired shares in several thermal baths in Austria, the technical management of the Vienna General Hospital (AKH Vienna) and the Austrian Vamed project business. The private equity fund PAI Partners took over 67 percent of the Vamed rehabilitation business. The remaining 33 percent will remain with Fresenius.
The separation from its Austrian subsidiary Vamed resulted in a quarterly loss for the German healthcare group Fresenius, as was announced yesterday.
